Abbott Laboratories experienced notable upward momentum driven primarily by key regulatory advances and positive product developments within its core medical device franchise. The company announced that the United States Food and Drug Administration approved enhanced features for its CardioMEMS heart failure system, introducing the CardioGuide HF App. This expansion enables patients to directly monitor pulmonary artery pressure measurements from their smartphones, improving remote care management and proactive treatment. The approval highlights Abbott’s ongoing expansion into digital health solutions, reinforcing investor confidence in the long-term growth trajectory of its medical technology segment.

Adding to the positive tone, recent…